Date of Presentation
5-4-2023 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
PMPS is defined as chronic neuropathic pain following breast cancer procedures in the ipsilateral arm, chest wall, axilla or shoulder.1-3 Approximately 20 to 50% of post mastectomy patients suffer from Post Mastectomy Pain Syndrome (PMPS).1 With more than 3.8 million breast cancer survivors, due to advances in treatment, there is increased importance in findings ways to better manage the quality of life of breast cancer survivors.1,4 Ketamine induces analgesic effects through its non-competitive antagonism of NDMA receptors.5 Low doses of ketamine infusion (20–30 mg x h−1) have been shown to produce analgesia in neuropathic pain states with benefits lasting up to three months.
Keywords
Ketamine, Pain Management, Mastectomy, Chronic Post-surgical Pain, Intraoperative Care
Disciplines
Anesthesia and Analgesia | Anesthesiology | Chemical and Pharmacologic Phenomena | Medicine and Health Sciences | Neoplasms | Obstetrics and Gynecology | Oncology | Pharmaceutical Preparations | Surgery | Surgical Procedures, Operative
Document Type
Poster
Included in
Anesthesia and Analgesia Commons, Anesthesiology Commons, Chemical and Pharmacologic Phenomena Commons, Neoplasms Commons, Obstetrics and Gynecology Commons, Oncology Commons, Pharmaceutical Preparations Commons, Surgery Commons, Surgical Procedures, Operative Commons
Perioperative Ketamine Use for Post Mastectomy Pain
PMPS is defined as chronic neuropathic pain following breast cancer procedures in the ipsilateral arm, chest wall, axilla or shoulder.1-3 Approximately 20 to 50% of post mastectomy patients suffer from Post Mastectomy Pain Syndrome (PMPS).1 With more than 3.8 million breast cancer survivors, due to advances in treatment, there is increased importance in findings ways to better manage the quality of life of breast cancer survivors.1,4 Ketamine induces analgesic effects through its non-competitive antagonism of NDMA receptors.5 Low doses of ketamine infusion (20–30 mg x h−1) have been shown to produce analgesia in neuropathic pain states with benefits lasting up to three months.